Takeda-partnered genomics startup hires first CEO

Seven months after launching with $70 million and a partnership with Takeda, genomics startup Ensoma Therapeutics has hired its first CEO in former BlueRock Therapeutics executive Emile Nuwaysir. Nuwaysir spent nearly five years at the helm of BlueRock as CEO, where he oversaw science similar to the platform Ensoma is currently pursuing. "BlueRock is a very disruptive ex vivo engineered cell therapy platform," Nuwaysir said. "Ensoma, I believe, is certainly the most disruptive in vivo ge ne-editing…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news